Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Shuyang He, Joseph Gleason, Nassir Habboubi, Robert Hariri, Xiaokui Zhang | ||||||||||||
Title | HUMAN PLACENTAL HEMATOPOIETIC STEM CELL DERIVED NATURAL KILLER CELLS FOR GLIOBLASTOMA IMMUNOTHERAPY | ||||||||||||
|
|||||||||||||
URL | https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi85/5619950?redirectedFrom=fulltext | ||||||||||||
Abstract Text | Neuro-Oncology, Vol. 21, Issue Suppl_6, Nov. 2019, Page vi85, EXTH-16 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CYNK-001 | Taniraleucel|CYNK001|CYNK 001 | CYNK-001 (taniraleucel) consists of allogeneic CD56+/CD3- natural killer cells expanded from CD34-positive placental stem cells, which may induce cytotoxicity against tumor cells and potentially demonstrates anti-tumor activity (Neuro-Oncology, Vol. 21, Issue Suppl_6, Nov. 2019, Page vi85, EXTH-16). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|